Detalhe da pesquisa
1.
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
Invest New Drugs
; 33(1): 201-14, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25344453
2.
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Gynecol Oncol
; 130(3): 511-7, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23665458
3.
Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies.
Anal Bioanal Chem
; 404(10): 3037-48, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23099526
4.
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Target Oncol
; 16(1): 47-57, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33211315
5.
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Target Oncol
; 16(1): 37-46, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33170484
6.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
J Clin Oncol
; 34(36): 4354-4361, 2016 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27998224
7.
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
J Clin Oncol
; 34(36): 4371-4380, 2016 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601554
8.
Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
Cancer Treat Rev
; 39(6): 664-72, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23434072
9.
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Clin Cancer Res
; 18(17): 4794-805, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22767668
10.
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 68(6): 1619-28, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21953275
11.
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
Curr Clin Pharmacol
; 5(3): 186-91, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20406171
12.
Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis.
Inflamm Bowel Dis
; 14(12): 1652-9, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18831034
13.
AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression.
J Biol Chem
; 279(15): 15678-87, 2004 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-14747476